Floatz logo

Acalabrutinib

Chronic Lymphocytic Leukaemia

Zulfa OmerSmall moleculePhase 4 / ApprovedActive
BBB
75/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
66/ 100
Competitive Position
89/ 100

Competitive context

71 Active assets in the Chronic Lymphocytic Leukaemia cohort.

Asset / SponsorPhaseRating
Humax-Cd20
Emory University
Phase 4BBB
Fludarabine
Ohio State University Comprehensive Cancer Center
Phase 4BBB
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
Zulfa Omer
Phase 4BBB
Cyclophosphamide
Ohio State University Comprehensive Cancer Center
Phase 4BBB
Obinutuzumab
Paolo Caimi, MD
Phase 3BB

View all 50 →

Same molecule, other indications

Acalabrutinib is also rated in:

follicular lymphomaDormant
BB
Indicative ·
70 / 100
View asset →
Grade 3a Follicular LymphomaDormant
BB
Indicative ·
70 / 100
View asset →
Chronic Lymphocytic Leukemia and Relapsed and Refractory Mantle Cell LymphomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →